Genmab A/S ADSGMAB
Close of Friday, October 23, 2026 · Genmab A/S ADS is trading above its Pivot, OnlyAlpha's long-term trend line.
Price
$43.79
vs its Pivot
+45.7%
OnlyAlpha Score
70
Trend
Above its Pivot
Last 12 months. Solid line: price. Dashed green: the Pivot.
Returns
| 1 month | Year to date | 1 year | 3 years / yr | 5 years / yr |
|---|---|---|---|---|
| +25.7% | +42.2% | +46.3% | +14.2% | -0.3% |
No dividend in the last 12 months.
Who runs and owns it
In these funds
IBB · 1.37%
Suppliers, customers and partners
GMAB sells to
| Johnson & Johnson (Janssen) | DARZALEX royalties 12-20% ($2,443M, ~66% of rev) |
| Novartis | Kesimpta 10% royalty |
Partners and deals
| AbbVie | EPKINLY co-commercialization |
From the companies' own annual reports filed with the SEC.
Healthcare · Biotech
Get GMAB in your free daily emailAfter every close: whether GMAB is above or below its Pivot, its OnlyAlpha Score, and any new buy or sell signal, along with the rest of your list.
Track GMAB free → Full Stock check
Track GMAB free → Full Stock check